The Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) has developed a robust system for data and safety monitoring, accomplished through the collaborative efforts of the three committees of the Clinical Protocol Scientific Review and Monitoring System (CPSRMS). These committees are: the Scientific Review Committee (SRC), the Data Monitoring Committee (DMC), and the Clinical Trial Audit Committee (CTAC). These committees are responsible for administering the Lurie Cancer Center's Data and Safety Monitoring Plan (DSMP), which was originally approved by the NCI in August of 2001, and has since undergone 10 revisions. The most recent revision to the plan was submitted to the NCI in May of 2012 and was accepted without comment at that time. In the previous competing CCSG application the assessment of Data and Safety Monitoring resulted in an Acceptable [Approved] status with no deficiencies noted. However, in section 9.2 PRMS, the previous CCSG competing submission included comments in the critique that relate directly to data and safety monitoring. First, it was suggested that the CTAC expand the auditing program to be more comprehensive. This has been done, and the audit strategy is described below. The second comment relates to DMC review for phase I studies and offered that a medical monitor may provide greater oversight for these trials if our phase I studies increase in number. A significant increase has not been seen, so this change has not been made, however both the SRC and DMC are mindful of and appreciate this recommendation. If our phase I program increases substantially, this change will be considered.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA060553-20
Application #
8761081
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$34,153
Indirect Cost
$11,948
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8

Showing the most recent 10 out of 316 publications